Click on image to view larger version.

Figure 1 Overview of intravenous glycoprotein IIb/IIIa trials by pooled analysis, with respect to 30-day death or myocardial infarction. Relative risk ratios for treatment with glycoprotein IIb/IIIa inhibitors as adjunctive therapy for percutaneous coronary intervention (PCI) and as empiric therapy for acute coronary syndromes (ACS) with electrocardiographic evidence of ischemia.